Compliance Administrative Support, 12 Months Fixed Term Contract.

Job description:
 

We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you.

We are currently recruiting for a Compliance Administrator to join the ADQC team for a 12 Months Fixed Term Contract.  The purpose of this role is to provide Administrative Support to the ADQC Team.

Our AD&QC team supports the development of products through analytical testing to facilitate manufacturing, shelf life setting and process development, ensuring appropriate quality controls and use of analytics.  The Compliance Administrator role is office based and requires on-site presence.

Your responsibilities in this role would be:

• Scanning and filing (paper and digital) of scientific documentation
• Preparing scientific documents for archiving.
• Managing documentation systems to ensure are easily retrievable and in line with departments Standard Operating Procedures (SOP).
• Providing general administration support, inclusive of updating departmental excel spreadsheets, maintaining office readiness, monitoring departmental training folders, stationary ordering and supporting the administrative onboarding of new starters.
• Maintaining departmental metrics within Microsoft Excel.
• Supporting the QC checking of departmental paperwork.

Profile description:

We are looking for:

• Educated to GCSE Level in Maths & English or equivalent.
• Proficient in Microsoft Office, Word, Excel, Outlook and PowerPoint.
• Previous documentation management administrative experience.
• Exposure to electronic or digital filing systems would be beneficial.
• An understanding and appreciation of working within a highly regulated environment is preferred, ideally GxP.
• Good communication skills in English both written and spoken.
• The ability to problem solve and collaborate cross departmentally.

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise

What’s in it for you:

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity

Collaborate. Contribute. Change lives

Closing date for applications is Friday 21st June 2024.

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.